Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.

193 Among those who had no detectable ctDNA at baseline, compared with single‐agent osimertinib, PFS was prolonged with the combination, although it did not reach statistical significance (median PFS, 33.3 vs. 30.3 months with osimertinib alone; HR, 0.93; 95% CI, 0.51–1.72).

also in 111,027 other papers